Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC)for Osteoarthritis of the First CarpoMetacarpal Joint

Inclusion Criteria: * Patient is diagnosed by the investigator to be medically acceptable for a surgical procedure? * Patient is aged 40 to 75 inclusive? * Patient has symptomatic osteoarthritis of the carpometacarpal (CMC-1) joint as demonstrated by a minimum DASH score of 40 at baseline? * Patient has pain in the target CMC joint as demonstrated by an average VAS pain score greater than or equal to 40 at baseline on a 100mm VAS? * Patient has radiographic evidence of Stage II OA with no free-floating bodies in the CMC-1 joint? * Radiographic Stage II OA is defined according to the Eaton-Glickel classification system (based upon lateral view) as follows: "Slight narrowing of the TM \[trapezio-metacarpal/CMC\] joint will be present with minimal sclerotic changes of the subchondral bone. There may be joint debris not exceeding 2 mm in diameter in the form of osteophytes or loose bodies The ST \[scapho-trapzeial joint\] should appear normal." * Patient has subluxation of less than one-third of the target CMC joint? * Patient agrees to return to the clinic for follow-up visits at the required times per protocol and follow the requirements of this protocol? * Patient is able and willing to provide voluntary consent to participate? Exclusion Criteria: * Patient has non-symptomatic osteoarthritis of the first CMC joint? * Patient has small bone or calcific fragments (spurs, osteophytes) in the target CMC joint greater than two millimeters (\>2mm) in diameter? * Patient has free floating bodies of any size within the target CMC joint? * Patient has radiographic/imaging evidence of significant osteoarthritic changes within the first metacarpal, or scaphotrapezotrapezoidal (STT) joint of the target wrist consistent with Stage III/IV OA, according to Eaton-Glickel, as defined below? "Stage III OA: The joint space will be markedly narrowed or obliterated with cystic changes, sclerotic bone, varying degrees of dorsal subluxation, and joint debris exceeding 2 mm in diameter. The ST joint will appear normal." "Stage IV OA: There is complete deterioration of the TM \[CMC\] joint as in stage III and, in addition, the ST joint will be narrowed with sclerotic and cystic changes apparent." * Patient has concomitant musculoskeletal pathology of the target hand, such as carpal tunnel syndrome, palmar tenosynovitis, scaphoulnate ligament instability/degeneration, ulnocarpal impaction syndrome, or trigger finger; * Patient has concomitant rheumatic disease (e.g., inflammatory rheumatoid arthritis, cutaneous psoriasis, polyarticular chondrocalcinosis, gout, fibromyalgia) or exhibits signs of metabolic disorders affecting the bone or joint (e.g., osteoporosis, osteomalacia, hyper- or hypo-parathyroidism, Paget's disease)? * Patient has an active infection, sepsis or osteomyelitis? * Patient has skin disease or eruption at the CMC target site? * Patient had previous surgery on the target CMC joint or on the wrist of the target hand? * Patient had significant injury to the target CMC joint within the 6 months prior to study enrollment or a significant permanent injury at any time prior to study enrollment? * Patient has a significant comorbid medical condition that could exacerbate pain symptoms or adversely affect physical functioning or healing of the thumb CMC joint (e.g. de Quervains disease, Ehlers-Danlos Syndrome, Complex Regional Pain Syndrome)? * Patient has had corticosteroid injections in the target CMC joint within 6 months prior to study enrollment? * Patient takes concomitant immunosuppressive therapy (e.g., oral/injectable glucocorticoids, alkylating agents, antimetabolites, antibodies, drugs acting on immunophilins \[Ciclosporin, Sirolimus\], interferons, opioids) that could adversely affect healing? * Patient has uncontrolled diabetes mellitus? * Patient takes anticoagulation and or antiplatelet therapy that cannot be stopped prior to surgery? * Patient is planning a pregnancy, or patient is pregnant and/or lactating? (If a subject becomes pregnant after enrollment in the study, then the subject will continue to be followed, even though she may miss some follow-up appointments. During the pregnancy, X-rays will not be performed.) * Patient is participating in any other clinical investigation that could impact the outcome of this study? * Patient has a known history of drug or alcohol abuse in the previous 12 months? * Patient has a history of, or is currently engaged in, litigation for musculoskeletal injuries or disorders or medical malpractice? * Patient has other life circumstances that the Investigator feels would interfere with study participation such as planned relocation, difficulty complying with schedule of study follow-up visits, is generally uncooperative?